CTKB
$4.25
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications.
Recent News
Cytek Biosciences Highlights Aurora Evo, Recurring Revenue Growth and 2026 Outlook at TD Cowen Conference
Cytek Biosciences (NASDAQ:CTKB) outlined its recent product launches, geographic diversification, and expectations for 2026 during a presentation and fireside chat at TD Cowen’s 42nd annual healthcare conference. CEO and Chairman Wenbin Jiang and CFO William McCombe discussed the company’s installed
How The Cytek Biosciences (CTKB) Story Is Shifting With New Targets And 2026 Guidance
Cytek Biosciences has seen its fair value estimate adjusted from US$5.75 to US$6.00, placing the stock in a slightly higher US$5 to US$6 price target framework. Analysts attribute this shift to a more constructive stance on the name, using clearer multi year models and a potential recovery in diagnostic tools to outline where Cytek could sit within the group. As you read on, you will see how these evolving targets and narratives might influence the way you track the story from here. Analyst...
Cytek (CTKB) Q4 2025 Earnings Call Transcript
At this time, I would like to welcome everyone to the Cytek Biosciences, Inc. fourth quarter 2025 earnings call. Earlier today, Cytek Biosciences, Inc. released financial results for the fourth quarter and year ended 12/31/2025. A copy of the news release is also available on the Investor Relations section of the Cytek Biosciences, Inc. website at investors.cytekbio.com.
Cytek Biosciences, Inc. Q4 2025 Earnings Call Summary
Moby summary of Cytek Biosciences, Inc.'s Q4 2025 earnings call
Cytek Biosciences Inc (CTKB) Q4 2025 Earnings Call Highlights: Record Revenue Amidst Challenges
Despite achieving record revenue, Cytek Biosciences Inc (CTKB) faces profitability pressures due to increased costs and a net loss in Q4 2025.